PanamaTimes

Thursday, Mar 28, 2024

AstraZeneca's vaccine rollout nets $275m in sales - but drags on its profits

AstraZeneca's vaccine rollout nets $275m in sales - but drags on its profits

The FTSE 100 drugs is actually being financially hurt by the pandemic despite its key role in trying to defeat the virus.

Today's quarterly results from AstraZeneca are a very timely reminder that, for all the debate about the drug-maker's involvement in the Oxford COVID vaccine, it is of very little importance to the financial fortunes of what is currently the fifth-largest company in the FTSE 100.

In fact, AZ is actually losing money on its involvement in the vaccine rollout.

AZ today reported sales for the first three months of the year of $7.3bn - up some 15% on the same period last year.

The vaccine is being sold at cost


To put that into context, $275m of that came from sales of the COVID vaccine AZ devised with the University of Oxford, representing a mere 4% of the total.

Moreover, because AZ is selling the vaccine at cost, the product actually turned out to be a drag on the company's earnings.

These came in at $1.63 per share, up 55% on the same period last year, way ahead of the $1.48 that analysts had been expecting.

AZ said today the figure would have been $1.66 were it not for the cost of producing the Oxford vaccine.

Given that, one could be forgiven for asking whether AZ regrets its involvement in the vaccine rollout, particularly given the criticism it has received in some countries and the legal battle with the European Commission in which the company now finds itself.

Pascal Soriot, AZ's chief executive, insisted today that was absolutely not the case.

AstraZeneca has found itself in a legal battle with the EU over the vaccine

He told reporters: "We actually got involved because we wanted to help and we thought we could make a difference and develop this vaccine.

"We never pretended that we were going to be perfect, and certainly, we've learned a few things along the way.

"But imagine if we had not stepped up.

"A year ago people were talking about there being 120, 130 different vaccines.

"Where are all those vaccines? They are nowhere.

"We never overpromised, we communicated what we thought we would achieve at the time based on the capacity that we had put together.

"We don't regret anything because we look forward, not backward.

"We did our very best to help the world, and overall the team should be very proud of the difference we've made and lives we've saved.

Chief executive Pascal Soriot said: "We are proud of what we have done"


"We are proud of what we have done, and only disappointed we could not do even more."

The disclosure is nonetheless significant because it is the first time that AZ, which with its manufacturing partners has so far supplied 300 million doses of the vaccine around the world, has actually disclosed its sales to date from the Oxford vaccine.

And, happily, it does not appear to have distracted investors too much from what was nonetheless a strong set of results and which at one point sent shares of AZ up by more than 4%.

This is a company which, a decade ago, looked like a sitting duck.

Sales from its blockbuster drugs were falling as they came off patent and attempts to deliver new blockbusters had misfired.

Sure enough, an unwanted bid from US giant Pfizer materialised in early 2014.

Mr Soriot and his colleagues fought off that approach partly by promising that investors were better off waiting for AZ to bring to market the new products in its pipeline.

Today's results prove again how AZ is delivering on that promise and especially in the key therapy area of oncology.

Sales were up 20% across the piece, with revenues for Tagrisso, the lung cancer treatment, rising by 17% to $1.2bn and sales of Lynparza, a treatment for ovarian cancer, up by 37% to $543m in the quarter.

Imfinzi, a treatment for lung and bladder cancer, saw its sales rise during the quarter by 20% to $556m.

The picture was no less encouraging in other therapy areas.

Farxiga, AZ's diabetes treatment, saw quarterly sales rise by 54% to $625m while sales of Fasenra, an asthma treatment, were up by 31% to $260m.

Elsewhere, there was little news on Alexion, the rare disease specialist specialist that AZ agreed to buy in December last year for $39bn.

The City was initially lukewarm on the deal but, gradually, shareholders appear to have come around to the idea.

AZ reiterated today that the deal is due to close between July and September this year.

There were one or two blemishes.

AstraZeneca fought off an unwanted approach from Pfizer in 2014


Sales of Brilinta, AZ's heart attack drug, were down by 8% during the quarter to $374m, reflecting fewer acute coronary syndrome hospital admissions, hitting demand in China in particular.

Similarly, sales of Pulmicort, another asthma treatment, fell by 13% to $330m as COVID-19 impacted the hospital treatment of respiratory patients and cheap generic versions of the drug appeared in some markets.

Those setbacks highlight the extent to which the pandemic has actually hurt AZ.

It has hit demand for some of AZ's other products by preventing patients with conditions other than COVID getting the hospital treatment they need.

And that is even before taking into account the fact that not only has producing the COVID vaccine hit its earnings, it has dragged AZ into unwanted legal rows, which will surely have been a drain on management time.

Mr Soriot could be forgiven for reflecting on the old adage that "no good deed goes unpunished".

Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
Apple warns against drying iPhones with rice
In a recent High Court hearing, the U.S. argued that Julian Assange endangered lives by releasing classified information.
Global Law Enforcement Dismantles Lockbit Ransomware Operation
Russian opposition leader Alexey Navalny has died at the Arctic prison colony
The President of Argentina Javier Mile does not fly private, he flies commercial, with the citizens he represents. And they LOVE him for it.
Bitcoin Reaches $50,000 for First Time in Over Two Years
Belo Horizonte: Brazil's Rising Carnival Hotspot for 2024
In El Salvador, the 'Trump of Latin America' stuns the world with a speech slamming woke policing after winning a landslide election
Tucker’s interview with Putin is over 50M views on X within the first 5 hours.
Finnish Airline, Finnair, is voluntarily weighing passengers to better estimate flight cargo weight
President Nayib Bukele has proudly announced El Salvador's remarkable achievement of becoming the safest nation in the Western Hemisphere.
Former Chilean President Sebastian Piñera Dies in Helicopter Crash
This farmer seems to understand science a bit more than the event organizer, Klaus Schwab.
Facebook turns 20: From Mark Zuckerberg's dormitory to a $1trn company
The Coolest Dictator in the World" on the Path to Victory in El Salvador
Macron, France and fake news
Indian-Origin Man 'King' Arrested For Smuggling $16 Million Drugs Into US
Can someone teach Americans that not every person with slanted eyes is Chinese?
Europe's Farmers Feeding the People, Protesting Against Politicians Who Do Nothing for Their Country and Serve Only Themselves at Taxpayers' Expense
Paris Restaurant That Inspired 'Ratatouille' Loses $1.6 Million Worth Of Wine
Brazilian Police Investigate Bolsonaro's Son for Alleged Illegal Spying
Police in Brazil Raid Residence of Bolsonaro Associate Over Allegations of Illegal Spying
Border Dispute Escalates as Texas Governor Vows Increased Razor Wire
OpenAI Enhances ChatGPT-4 Model, Potentially Addressing AI "Laziness" Issue
The NSA finally acknowledges spying on Americans by acquiring sensitive data
Report Reveals Toxic Telegram Group Generating X-Rated AI-Generated Fake Images of Taylor Swift
US Border Patrol States 'No Plans' to Remove Razor Wire Installed in Texas
Bitcoin Experiences Approximately 20% Decline in Value
Klaus Schwab recently appointed himself as the Earth's "trustee of the future."
DeSantis Drops Out, Endorses Trump.
Nikki Haley said former President Trump is "just not at the same level" of mental fitness as he was while president in 2016.
Residents of a southern Mexican town set the government palace on fire in response to the police killing of a young man
Samsung Launches AI-Driven Galaxy S24, Ushering in New Smartphone Era
Judge Questions SEC's Regulatory Overreach in Coinbase Lawsuit
The Ecuador prosecutor who was investigating the television studio attack, has been assassinated.
Is artificial intelligence the solution to cyber security threats?
Vivek Ramaswamy suspends his US election campaign and endorses Trump.
Viral Satire: A Staged Satirical Clip Mistaken as Real Footage from the 2024 World Economic Forum in Davos
The AI Revolution in the Workforce: CEOs at Davos Predict Major Job Cuts in 2024
Ecuador Reports 178 Hostages in Prison Gang Standoff
The Startling Cuban Espionage Case That Has Rattled the US Government
Two Armed Men in Ecuador, Dressed as Batman and The Joker Storm the Streets.
Armed Gang Raids Ecuadorian TV Station Following State of Emergency Declaration
Anti-Democratic Canada: Journalist Arrested for Questioning Canadian Finance Minister on Support of Terrorist Group
Ecuador's 'Most-Wanted' Criminal Vanishes from Prison
Mexican Cartel Supplied Wi-Fi to Locals Under Threat of Fatal Consequences for Non-Compliance
Border Surge Leads to Over 11,000 Migrants Waiting in Northern Mexico
Outsider Candidates Triumph in Latin American Elections
As Argentina Goes to the Polls, Will the Proposal to Replace the Peso with the Dollar Secure Votes?
Fatal Shark Attack Claims Life of Boston Woman Paddleboarding Near Bahamas Resort, According to Police
×